Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: Impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma

Pathology

Volumn 46, Issue 6, 2014, Pages 509-517

  Dvorak, Katerina ^a   Aggeler, Birte ^a   Palting, John ^a   McKelvie, Penny ^b   Ruszkiewicz, Andrew ^c   Waring, Paul ^d  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

BRAF V600E; Colon cancer; DNA sequencing; Immunohistochemistry; Thyroid cancer

Indexed keywords

B RAF KINASE; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADENOCARCINOMA; ANIMAL; CARCINOMA; COLORECTAL TUMOR; DISEASE MODEL; DNA SEQUENCE; FEMALE; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MALE; METABOLISM; MOUSE; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; SENSITIVITY AND SPECIFICITY; THYROID TUMOR; TUMOR CELL LINE; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; BIOMARKERS, TUMOR; CARCINOMA; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HETEROGRAFTS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; THYROID NEOPLASMS;

EID: 84923641992     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0000000000000119     Document Type: Article

References (39)

1. Cantwell-Dorris ER, O'Leary JJ, Sheils OM. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther 2011; 10: 385-94.
2. Rubinstein JC, Sznol M, Pavlick AC, et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med 2010; 8: 67.
3. Pakneshan S, Salajegheh A, Smith RA, Lam AK. Clinicopathological relevance of BRAF mutations in human cancer. Pathology 2013; 45: 346-56.
4. Grisham RN, Iyer G, Garg K, et al. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer 2013; 119: 548-54.
5. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011; 364: 2305-15.
6. Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012; 120: 2700-3.
7. Dias-Santagata D, Lam Q, Vernovsky K, et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One 2011; 6: e17948.
8. Mesteri I, Bayer G, Meyer J, et al. Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E. Mod Pathol 2014; 27: 135-44.
9. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
10. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-65.
11. Xu Q, Xu AT, Zhu MM, Tong JL, Xu XT, Ran ZH. Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis. J Dig Dis 2013; 14: 409-16.
12. Capper D, Voigt A, Bozukova G, et al. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Int J Cancer 2013; 133: 1624-30.
13. Toon CW, Walsh MD, Chou A, et al. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am J Surg Pathol 2013; 37: 1592-602.
14. Thiel A, Heinonen M, Kantonen J, et al. BRAF mutation in sporadic colorectal cancer and Lynch syndrome. Virchows Arch 2013; 463: 613-21.
15. Day F, Singh S, Shanmugam K, et al. A mutant BRAF V600E-specific immunohistochemistry assay: Correlation with molecular mutation status and clinical outcome in colorectal cancer. Target Oncol 2014; 9: (in press).
16. Tie J, Gibbs P, Lipton L, et al. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer 2011; 128: 2075-84.
17. Toon CW, Chou A, Desilva K, et al. BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer. Mod Pathol 2013; 27: 644-50.
18. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013; 309: 1493-501.
19. Elisei R, Viola D, Torregrossa L, et al. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab 2012; 97: 4390-8.
20. Howell GM, Nikiforova MN, Carty SE, et al. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol 2013; 20: 47-52.
21. Kim SJ, Lee KE, Myong JP, et al. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg 2012; 36: 310-7.
22. McKelvie PA, Chan F, Yu Y, et al. The prognostic significance of the BRAF V600E mutation in papillary thyroid carcinoma detected by mutationspecific immunohistochemistry. Pathology 2013; 45: 637-44.
23. Capper D, Berghoff AS, Magerle M, et al. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 2012; 123: 223-33.
24. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011; 122: 11-9.
25. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
26. Ziai J, Hui P. BRAF mutation testing in clinical practice. Expert Rev Mol Diagn 2012; 12: 127-38.
27. Ahn S, Lee J, Sung JY, et al. Comparison of three BRAF mutation tests in formalin-fixed paraffin embedded clinical samples. Korean J Pathol 2013; 47: 348-54.
28. Anderson S, Bloom KJ, Vallera DU, et al. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma. Arch Pathol Lab Med 2012; 136: 1385-91.
29. Adackapara CA, Sholl LM, Barletta JA, Hornick JL. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma. Histopathology 2013; 63: 187-93.
30. Affolter K, Samowitz W, Tripp S, Bronner MP. BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma. Genes Chromosomes Cancer 2013; 52: 748-52.
31. Desai J, Day F, Muranyi A, et al. A highly sensitive immunohistochemical assay to detect BRAF V600E mutations in patients with colorectal cancer. Ann Oncol 2012; 23: 383-1383.
32. Sinicrope FA, Smyrk TC, Tougeron D, et al. Mutation-specific antibody detects mutant BRAF(V600E) protein expression in human colon carcinomas. Cancer 2013; 119: 2765-70.
33. Bullock M, O'Neill C, Chou A, et al. Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma. Endocr Relat Cancer 2012; 19: 779-84.
34. Zagzag J, Pollack A, Dultz L, et al. Clinical utility of immunohistochemistry for the detection of the BRAF V600E mutation in papillary thyroid carcinoma. Surgery 2013; 154: 1199-204.
35. Koperek O, Kornauth C, Capper D, et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol 2012; 36: 844-50.
36. Sperveslage J, Gierke M, Capper D, et al. VE1 immunohistochemistry in pituitary adenomas is not associated with BRAF V600E mutation. Acta Neuropathol 2013; 125: 911-2.
37. Farzin M, Toon CW, Clarkson A, Sioson L, Gill AJ. BRAF V600E mutation specific immunohistochemistry with clone VE1 is not reliable in pituitary adenomas. Pathology 2014; 46: 79-80.
38. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29: 1239-46.
39. Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol 2013; 37: 61-5.